Sputum neutrophils as a biomarker in COPD: Findings from the ECLIPSE study

Dave Singh, Lisa Edwards, Ruth Tal-Singer, Stephen Rennard

Research output: Contribution to journalArticle

98 Citations (Scopus)

Abstract

Introduction: The percentage of neutrophils in sputum are increased in COPD patients, and may therefore be a biomarker of airway inflammation. We studied the relationships between sputum neutrophils and FEV1, health status, exacerbation rates, systemic inflammation and emphysema, and long term variability at 1 year.Methods: Sputum samples were obtained from 488 COPD patients within the ECLIPSE cohort. 359 samples were obtained at baseline, and 297 after 1 year. 168 subjects provided samples at both visits. Serum interleukin-6 (IL-6), IL-8, surfactant protein D and C-reactive protein levels were measured by immunoassays. Low-dose CT scans evaluated emphysema.Results: Sputum neutrophil % increased with GOLD stage. There was a weak association between % sputum neutrophils and FEV1 % predicted (univariate r2 = 0.025 and 0.094 at baseline and year 1 respectively, p < 0.05 after multivariate regression). Similar weak but significant associations were observed between neutrophil % and health status measured using the St Georges Respiratory Questionairre. There were no associations between neutrophils and exacerbation rates or emphysema. Associations between sputum neutrophils and systemic biomarkers were non-significant or similarly weak. The mean change over 1 year in neutrophil % was an increase of 3.5%.Conclusions: Sputum neutrophil measurements in COPD are associated weakly with FEV1 % predicted and health status. Sputum neutrophil measurements were dissociated from exacerbation rates, emphysema and systemic inflammation.

Original languageEnglish (US)
Article number77
JournalRespiratory Research
Volume11
DOIs
StatePublished - Jun 15 2010

Fingerprint

Sputum
Chronic Obstructive Pulmonary Disease
Neutrophils
Biomarkers
Emphysema
Health Status
Inflammation
Dilatation and Curettage
Interleukin-8
Immunoassay
Surface-Active Agents
Interleukin-6
Proteins

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Sputum neutrophils as a biomarker in COPD : Findings from the ECLIPSE study. / Singh, Dave; Edwards, Lisa; Tal-Singer, Ruth; Rennard, Stephen.

In: Respiratory Research, Vol. 11, 77, 15.06.2010.

Research output: Contribution to journalArticle

Singh, Dave ; Edwards, Lisa ; Tal-Singer, Ruth ; Rennard, Stephen. / Sputum neutrophils as a biomarker in COPD : Findings from the ECLIPSE study. In: Respiratory Research. 2010 ; Vol. 11.
@article{18f0fc05ddbf489090207b6689108267,
title = "Sputum neutrophils as a biomarker in COPD: Findings from the ECLIPSE study",
abstract = "Introduction: The percentage of neutrophils in sputum are increased in COPD patients, and may therefore be a biomarker of airway inflammation. We studied the relationships between sputum neutrophils and FEV1, health status, exacerbation rates, systemic inflammation and emphysema, and long term variability at 1 year.Methods: Sputum samples were obtained from 488 COPD patients within the ECLIPSE cohort. 359 samples were obtained at baseline, and 297 after 1 year. 168 subjects provided samples at both visits. Serum interleukin-6 (IL-6), IL-8, surfactant protein D and C-reactive protein levels were measured by immunoassays. Low-dose CT scans evaluated emphysema.Results: Sputum neutrophil {\%} increased with GOLD stage. There was a weak association between {\%} sputum neutrophils and FEV1 {\%} predicted (univariate r2 = 0.025 and 0.094 at baseline and year 1 respectively, p < 0.05 after multivariate regression). Similar weak but significant associations were observed between neutrophil {\%} and health status measured using the St Georges Respiratory Questionairre. There were no associations between neutrophils and exacerbation rates or emphysema. Associations between sputum neutrophils and systemic biomarkers were non-significant or similarly weak. The mean change over 1 year in neutrophil {\%} was an increase of 3.5{\%}.Conclusions: Sputum neutrophil measurements in COPD are associated weakly with FEV1 {\%} predicted and health status. Sputum neutrophil measurements were dissociated from exacerbation rates, emphysema and systemic inflammation.",
author = "Dave Singh and Lisa Edwards and Ruth Tal-Singer and Stephen Rennard",
year = "2010",
month = "6",
day = "15",
doi = "10.1186/1465-9921-11-77",
language = "English (US)",
volume = "11",
journal = "Respiratory Research",
issn = "1465-9921",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Sputum neutrophils as a biomarker in COPD

T2 - Findings from the ECLIPSE study

AU - Singh, Dave

AU - Edwards, Lisa

AU - Tal-Singer, Ruth

AU - Rennard, Stephen

PY - 2010/6/15

Y1 - 2010/6/15

N2 - Introduction: The percentage of neutrophils in sputum are increased in COPD patients, and may therefore be a biomarker of airway inflammation. We studied the relationships between sputum neutrophils and FEV1, health status, exacerbation rates, systemic inflammation and emphysema, and long term variability at 1 year.Methods: Sputum samples were obtained from 488 COPD patients within the ECLIPSE cohort. 359 samples were obtained at baseline, and 297 after 1 year. 168 subjects provided samples at both visits. Serum interleukin-6 (IL-6), IL-8, surfactant protein D and C-reactive protein levels were measured by immunoassays. Low-dose CT scans evaluated emphysema.Results: Sputum neutrophil % increased with GOLD stage. There was a weak association between % sputum neutrophils and FEV1 % predicted (univariate r2 = 0.025 and 0.094 at baseline and year 1 respectively, p < 0.05 after multivariate regression). Similar weak but significant associations were observed between neutrophil % and health status measured using the St Georges Respiratory Questionairre. There were no associations between neutrophils and exacerbation rates or emphysema. Associations between sputum neutrophils and systemic biomarkers were non-significant or similarly weak. The mean change over 1 year in neutrophil % was an increase of 3.5%.Conclusions: Sputum neutrophil measurements in COPD are associated weakly with FEV1 % predicted and health status. Sputum neutrophil measurements were dissociated from exacerbation rates, emphysema and systemic inflammation.

AB - Introduction: The percentage of neutrophils in sputum are increased in COPD patients, and may therefore be a biomarker of airway inflammation. We studied the relationships between sputum neutrophils and FEV1, health status, exacerbation rates, systemic inflammation and emphysema, and long term variability at 1 year.Methods: Sputum samples were obtained from 488 COPD patients within the ECLIPSE cohort. 359 samples were obtained at baseline, and 297 after 1 year. 168 subjects provided samples at both visits. Serum interleukin-6 (IL-6), IL-8, surfactant protein D and C-reactive protein levels were measured by immunoassays. Low-dose CT scans evaluated emphysema.Results: Sputum neutrophil % increased with GOLD stage. There was a weak association between % sputum neutrophils and FEV1 % predicted (univariate r2 = 0.025 and 0.094 at baseline and year 1 respectively, p < 0.05 after multivariate regression). Similar weak but significant associations were observed between neutrophil % and health status measured using the St Georges Respiratory Questionairre. There were no associations between neutrophils and exacerbation rates or emphysema. Associations between sputum neutrophils and systemic biomarkers were non-significant or similarly weak. The mean change over 1 year in neutrophil % was an increase of 3.5%.Conclusions: Sputum neutrophil measurements in COPD are associated weakly with FEV1 % predicted and health status. Sputum neutrophil measurements were dissociated from exacerbation rates, emphysema and systemic inflammation.

UR - http://www.scopus.com/inward/record.url?scp=77956686967&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956686967&partnerID=8YFLogxK

U2 - 10.1186/1465-9921-11-77

DO - 10.1186/1465-9921-11-77

M3 - Article

C2 - 20550701

AN - SCOPUS:77956686967

VL - 11

JO - Respiratory Research

JF - Respiratory Research

SN - 1465-9921

M1 - 77

ER -